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Abstract
Background: HIV prevention trials conducted among disadvantaged vulnerable at-risk populations in developing 
countries present unique ethical dilemmas. A key concern in bioethics is the validity of informed consent for trial 
participation obtained from research subjects in such settings. The purpose of this study was to investigate the 
effectiveness of a continuous informed consent process adopted during the MDP301 phase III vaginal microbicide trial 
in Mwanza, Tanzania.
Methods: A total of 1146 women at increased risk of HIV acquisition working as alcohol and food vendors or in bars, 
restaurants, hotels and guesthouses have been recruited into the MDP301 phase III efficacy and safety trial in Mwanza. 
During preparations for the trial, participatory community research methods were used to develop a locally-
appropriate pictorial flipchart in order to convey key messages about the trial to potential participants. Pre-recorded 
audio tapes were also developed to facilitate understanding and compliance with gel-use instructions. A 
comprehension checklist is administered by clinical staff to all participants at screening, enrolment, 12, 24, 40 and 50 
week follow-up visits during the trial. To investigate women's perceptions and experiences of the trial, including how 
well participants internalize and retain key messages provided through a continuous informed consent process, a 
random sub-sample of 102 women were invited to participate in in-depth interviews (IDIs) conducted immediately 
after their 4, 24 and 52 week follow-up visits.
Results: 99 women completed interviews at 4-weeks, 83 at 24-weeks, and 74 at 52 weeks (a total of 256 interviews). In 
all interviews there was evidence of good comprehension and retention of key trial messages including that the gel is 
not currently know to be effective against HIV; that this is the key reason for conducting the trial; and that women 
should stop using gel in the event of pregnancy.
Conclusions: Providing information to trial participants in a focussed, locally-appropriate manner, using methods 
developed in consultation with the community, and within a continuous informed-consent framework resulted in high 
levels of comprehension and message retention in this setting. This approach may represent a model for researchers 
conducting HIV prevention trials among other vulnerable populations in resource-poor settings.
Trial registration: Current Controlled Trials ISRCTN64716212
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Background
HIV prevention trials present a number of unique ethical
dilemmas for researchers [1-10]. In many developed and
developing country settings, prevention trials are feasible
only among vulnerable sub-populations at increased risk
of HIV and sexually transmitted infections (STIs) [11,12].
Stigma, income poverty, lack of formal education, illiter-
acy, and in some at-risk populations, impaired mental
state due to alcohol and/or other drug use, mean that
obtaining truly informed consent for research participa-
tion can be fraught with difficulties in such settings. Vul-
nerable, desperate subjects are likely to weigh up the
potential risks and benefits of trial participation using
very different criteria and value judgments compared to
less vulnerable subjects [13-17]. Comprehension and
retention of key information provided during informed
consent procedures, such as overall research objectives or
the likelihood and nature of product-related adverse
events, may be influenced not only by a subject's educa-
tional background or literacy level but also by language
barriers and differences in socio-cultural perspectives of
health and disease between subjects and the research
team [3,14]. Traditional informed consent procedures,
based on the use of a written Participant Information
Sheet (PIS) and completion of a standardised Informed
Consent Form (ICF), are the cornerstone of the Interna-
tional Committee on Harmonization (ICH) Good Clini-
cal Practice (GCP) Guidelines but are now widely
recognised to be insufficient alone in obtaining informed
consent in such settings [14-16,18]. Innovative
approaches to information delivery include the use of an
educational video during informed consent for an HIV
prevention trial in Port-au-Prince, Haiti, which was asso-
ciated with high levels of accurate message retention
when combined with a face-to-face educational session
with a trained study counsellor [18]. Other researchers
have affirmed the importance of community engagement
in the design of locally-appropriate, culturally resonant
informed consent procedures [3,19-21]. The need to con-
sider informed consent as a process (important through-
out the period of research participation) rather than a
discrete activity (relevant at study entry only) has increas-
ingly been recognised in both developed and developing
country settings [14,16,18,22,23].
Mwanza is one of six centres in sub-Saharan Africa par-
ticipating in the Microbicides Development Programme
(MDP), an international partnership for the development
of vaginal microbicides for HIV prevention, funded by
the UK Department for International Development and
Medical Research Council (MRC), and coordinated by
the MRC Clinical Trials Unit and Imperial College, Lon-
don [24]. A feasibility study [25] was carried out among
an occupational cohort of women at increased risk of
HIV infection and sexually transmitted infections (STIs)
in ten administrative wards in Mwanza City, northern
Tanzania between July 2002 and March 2005 in prepara-
tion for the on-going MDP301 randomized placebo-con-
trolled efficacy and safety trial of the candidate vaginal
microbicide PRO2000/5 Gel (Endo Pharmaceuticals,
USA), which started in November 2005. Women working
in food and recreational facilities, including modern bars,
traditional bars (known as vilabu or pombe shops in Tan-
zania), restaurants, hotels, guesthouses, groceries and as
informal food vendors (known locally as mamalishe),
were eligible to participate. Research conducted at a
number of sites in Tanzania suggests that some women in
this occupational group periodically supplement their
income through transactional sex [26,27] and are hence at
increased risk of STIs and HIV infection [25,28-31].
In this paper we describe how a participatory, multi-
method, continuous informed consent process developed
by researchers, study participants and community stake-
holders during the preliminary feasibility and pilot phases
of the program resulted in high levels of comprehension
and message retention in the MDP301 vaginal microbi-
cide trial in Mwanza. This approach may represent a
model for researchers conducting HIV prevention trials




The design of the microbicide trial feasibility study in
Mwanza and the baseline socio-demographic, behav-
ioural and biomedical characteristics of study partici-
pants have previously been described [25]. In brief,
following participatory community mapping to identify
eligible food and recreational facilities in ten administra-
tive wards in Mwanza City, a community-based clinic was
established in a guesthouse in each ward by October
2002. Study clinics provided free sexual and reproductive
health services to participants including voluntary HIV
counselling and testing; STI syndromic management;
family planning advice and health education. Participants
found to be HIV positive were referred to a specialist
local public health provider for clinical assessment and
care which included antiretroviral provision if appropri-
ate. In addition, an informal referral network of local
non-governmental and community-based organizations
(NGOs and CBOs) providing care and support for fami-
lies living with HIV and AIDS was established. Partici-
pants with general medical or gynaecological problems
were referred to established local care providers for spe-
cialist clinical care. A total of 1573 women were enrolled
and followed up at three-monthly intervals for up to 24
months. The feasibility study ended in March 2005 with
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the completion of a small pilot study, conducted among
59 participants, to investigate the acceptability of
HPTN035 Placebo Gel in this study population and the
feasibility and acceptability of proposed clinical trial pro-
cedures [32].
Following the successful completion of the feasibility
and pilot studies in Mwanza, the MDP301 efficacy and
safety trial commenced among the same study population
in November 2005. A total of 1146 HIV sero-negative
women were enrolled into the main trial in Mwanza,
which completed follow-up in June 2009.
Community engagement strategies
During the MDP301 feasibility study, a variety of commu-
nity liaison strategies were developed at the six research
centres in Africa. In Mwanza, a participatory approach
was adopted and has been described in detail elsewhere
[33,34]. Key objectives were to investigate the feasibility
of a participatory model of community liaison in this con-
text, facilitated by the use of tools adapted from partici-
patory learning and action techniques (such as listing,
scoring, ranking, and diagramming); to establish effective
locally-appropriate mechanisms of representation for
women participating in the feasibility study; and to build
a robust system capable of identifying and responding to
key project-related concerns among participants and the
broader community. This strategy facilitated open dia-
logue and two-way communication between researchers
and study participants and provided a highly-flexible
accessible mechanism through which to disseminate
information on research activities at community level.
The system was designed around 78 geographical clusters
of food and recreational facilities within the ten study
wards with representatives at cluster and ward level
elected in a process facilitated by the project Community
Liaison Officer (CLO, CS). A city-level Community Advi-
sory Committee (CAC) was established with representa-
tives from each ward. Secondary stakeholders
representing local public-sector and non-governmental
health and social care providers formed a trial Stakehold-
ers' Advisory Group (SAG), which includes two CAC rep-
resentatives.
The community liaison system was a key integral com-
ponent of the MDP301 trial in Mwanza and through the
network of cluster, ward and city-level representatives
provided valuable input to the management of the trial
e.g. development and review of locally appropriate stan-
dard of care guidelines [35,36].
Informed consent procedures during the feasibility and 
pilot studies
During the feasibility study in Mwanza, project field-
workers conducted orientation and mobilisation meet-
ings at facility-level during which women were advised on
study objectives, clinical procedures and other study-
related issues. Fieldworkers demonstrated the blood col-
lection and clinical examination instruments to be used
and passed these around the group so that women could
see and handle these items for themselves (Figure 1).
Women were encouraged to ask questions about the
study and invited to attend an initial clinic visit at which
they were advised they would have a more detailed dis-
cussion with a member of the clinical team prior to com-
pleting formal informed consent procedures (including
providing a signature or witnessed thumbprint to con-
firm their understanding of key study objectives and pro-
cedures) and enrolling in the feasibility study. Every
participant was given a Participant Information Sheet
(PIS) in Swahili and a copy of their completed Informed
Consent Form (ICF) to take home.
The relatively high early losses to follow-up observed
during the feasibility study[25], coupled with anecdotal
feedback from clinic staff and fieldworkers, and informa-
tion collected from study participants in community par-
ticipatory workshops, focus group discussions (FGDs)
and in-depth interviews (IDIs) [34], suggested that mis-
Figure 1 Fieldworker showing a speculum to women attending a 
facility-based meeting.
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conceptions and misunderstanding about study objec-
tives were relatively common during the feasibility study
and that these may have affected clinic re-attendance.
These findings led to a reappraisal of informed consent
procedures at the site, culminating in a variety of new
approaches being tested in the MDP301 Pilot Study,
including a pictorial flipchart developed through consul-
tation with members of the Community Advisory Com-
mittee (Figure 2) and subsequently used by project
fieldworkers to provide information to potential study
participants at facility-based community meetings. Audio
tape recordings and pictorial instructions providing
information on gel use were also piloted. A site-specific
comprehension assessment, which included a qualitative
component and a standardised written checklist, was
used to evaluate how accurately study participants were
able to retain key messages relating to pilot study objec-
tives. IDIs were conducted in order to explore compre-
hension and message retention in more depth. The high
levels of information retention and comprehension
observed during the pilot study led to a revised package
of informed consent tools and procedures being taken
into the main MDP301 phase III clinical trial.
Informed consent procedures during the MDP301 trial in 
Mwanza
A continuous consent process was developed for the
main trial in Mwanza, based on experience gained during
the feasibility and pilot study phases of the program, and
designed to facilitate accurate and comprehensive mes-
sage retention from the point of first contact in the com-
munity to completion of the final study visit at 52 weeks
(Figure 3). Each step in the process required around 30-
45 minutes. This approach was facilitated by the sponsors
of the MDP301 multicentre phase III trial who provided
each trial site with a list of generic key messages to be
provided to participants but also strongly encouraged
sites to develop locally-appropriate strategies for commu-
nicating these messages to participants as part of the
informed consent process, in recognition of the diversity
of socio-cultural settings within which this research was
being undertaken.
The MDP trial investigators decided to focus on assess-
ing the comprehension of three critical issues: that gel
may not protect participants from HIV acquisition; that
consistent condom use will prevent HIV infection; and
that in the event of pregnancy, gel should be discontin-
ued. An MDP301 trial-specific Comprehension Checklist
(Figure 4) was therefore developed and administered by
clinical staff to participants at screening, enrolment, 12,
24, 40 and 52 week follow-up visits. Staff provided imme-
diate feedback to participants once the checklist was
completed, reviewing any incorrect or unclear responses
to each of the three key messages to ensure participants
had adequate understanding prior to proceeding with the
scheduled visit.
To investigate women's perceptions and experiences of
the trial, including how well participants understand and
retain key messages provided through a continuous
informed consent process, a random sub-sample of 100
women were invited to participate in in-depth interviews
(IDIs) conducted immediately after their 4, 24 and 52
week follow-up visits. IDIs evaluated participant under-
standing and recall as well as assessing comprehension in
the context of wider participant perceptions about the
trial. This enabled researchers to evaluate message com-
prehension and retention but to also investigate message
internalization in terms of how understanding was incor-
porated into prevailing beliefs and perceptions of HIV
risk, female sexual agency and other issues, such as
women's hopes that gel would be effective. IDIs were con-
ducted in Swahili using a semi-structured, standardised
interview guide and recorded with the participant's per-
mission. Participants were each asked the same questions
relating to the informed consent process at each time
point. Transcripts were written in Swahili and translated
into English, which were then read and corrected by the
original interviewer, in consultation with the Social Sci-
Figure 2 Reviewing an early version of the pictorial flipchart with 
CAC members.
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ence Research Coordinator (SL). Qualitative data were
analysed using QSR-Nvivo 2.0 software (QSR Interna-
tional, Australia), using a coding frame developed by the
research team, which was supplemented as themes
emerged in the course of analysis. IDIs were coded for a
variety of key themes in addition to comprehension and
informed consent issues, including gel use and accept-
ability; the acceptability of trial procedures; factors deter-
mining condom use; and intravaginal hygiene practices.
Data analysis was carried out by the Social Science
Research Coordinator (SL) and MDP301 Mwanza Trial
Coordinator (AV), who checked their interpretations of
the data with the field research team, going back to the
Swahili documents for verification where necessary. For
each of the three key trial messages in the Comprehen-
sion Checklist, participants were categorised into two
broad groups based on their responses and comments
during in-depth interviews. Simple quantitative univari-
ate analysis was carried out using the Statcalc function of
EpiInfo 2000 (CDC, Atlanta, USA).
Ethical considerations
Ethical clearance for this research was obtained from the
National Medical Research Coordinating Committee in
Tanzania and the Ethics Committee of the London
School of Hygiene and Tropical Medicine in the UK. Pic-
torial flipcharts, audio tapes, pictorial gel use instruc-
tions, comprehension checklists, Participant Information
Sheets (PIS) and Informed Consent Forms (ICFs) in Eng-
lish and Swahili were all approved as part of the ethical
review process. Written informed consent (signature or
witnessed thumbprint) was obtained from all participants
at both screening and enrolment visits, in accordance
with the International Committee on Harmonization
(ICH) Good Clinical Practice (GCP) guidelines. Separate
written informed consent for participation in the IDIs
was also obtained from each participant.
Results and Discussion
A total of 256 interviews were carried out, comprising 99
women completing IDIs at 4-weeks, 83 at 24-weeks, and
74 at 52 weeks. The majority of respondents at all time
Figure 3 Continuous informed consent process, MDP301 trial, Mwanza.
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Figure 4 Comprehension Checklist, MDP301 trial.
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points appeared to have understood and retained key
information provided through the informed consent pro-
cess, including overall trial objectives and messages
related to gel, condom use and pregnancy (Table 1).
There appeared to be no significant trends in retention or
understanding during the period of follow-up.
Why is the trial being carried out?
All women interviewed appeared to have a sound basic
understanding of why the trial was being conducted, for
example:
'They are trying the gel so that they may be sure if it
will help to prevent infections of HIV/AIDS'
'I am participating in the study because we want to
know if the gel can help us. Not me alone, but that it
will benefit all people, even the whole world, the whole
of Tanzania'
'They are doing the research because a woman does
not have the ability to force a man to use a condom
...this is the reason it has been developed, for a woman
to protect herself against HIV'
Complex issues such as the research development pro-
cess, the concept of a placebo gel and the requirement for
randomisation and blinding in the experimental trial
design also appear to have been broadly understood by
trial participants, despite low levels of literacy and educa-
tional attainment among women in this occupational
group [25]:
'The gel has gone through research ...three different
researches, starting with a research on animals
through to a research on human beings. At present it is
at the third type of research, they are checking the
effectiveness of the gel ...it is being checked to see if it
can work in the bodies of people'
"When we went to the clinic they told us that there
were two types of gel, there is a gel with medicine [jeli
yenye dawa] and a gel without medicine [jeli bila
dawa], now for us that use the gel we do not know if it
has medicine or not."
'The gel is here for the purpose of a research of HIV
infection. They test it to see whether it does or does not
prevent. It means that if even those who have com-
pleted 52 weeks do not know yet whether it has [effec-
tive] medicine. We too will complete and leave our
colleagues participating while it is still under research'
'I am not sure with gel because we haven't reached the
end of the study, we don't know yet if it protects or not'
Many of these issues were explored in depth with com-
munity representatives and local stakeholders in Mwanza
during participatory community workshops, CAC and
SAG meetings during the earlier feasibility and pilot stud-
ies [34] in order to appropriately frame these concepts
within the consent process (e.g. pictorial representation
of randomisation in the site-specific flipchart; appropri-
ate terminology for the placebo gel (jeli ya placebo; jeli
bila dawa ['gel without medicine']) that avoid potentially
misleading terms, such as mafuta (ointment, oil), which
can have overly positive medical overtones). Reinforcing
these and other messages from point of first community
contact, through screening, enrolment and trial follow-
up has been a core principle in Mwanza and may help
explain the high levels of trial message comprehension
Table 1: Comprehension and retention of key informed consent messages at 4, 24 and 52 weeks follow-up, MDP301 Trial, 
Mwanza1
Message N (%) of participants with accurate message retention at each visit Chi square test for linear trend, 
4 to 52 weeks (p-value)
Wk 4 (n = 99) Wk 24 (n = 83) Wk 52 (n = 74) All wks combined (N = 256)
Key message 1:
Gel may not protect her 
from HIV
76 (76.8%) 59 (71.1%) 62 (83.8%) 197 (77.0%) 0.90 (p = 0.341)
Key message 2:
Condoms will protect 
her from HIV
82 (82.8%) 69 (83.1%) 59 (79.7%) 210 (82.0%) 0.25 (p = 0.619)
Key message 3:
She will have to stop 
using gel if she becomes 
pregnant
92 (92.9%) 78 (94.0%) 69 (93.3%) § 239 (93.3%) 0.19 (p = 0.665)
1A single researcher made an assessment of message retention at each time point; it was therefore not possible to calculate a Kappa statistic for 
concordance
§ There was one missing value at wk 52
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and retention observed among women in this cohort. In
addition, the participatory community liaison system
(CLS) developed in Mwanza is thought to have facilitated
key message reinforcement at facility, cluster and ward
level meetings. For example, informal feedback via com-
munity representatives and project fieldworkers, supple-
mented and validated by formal qualitative research
methods [34], allowed misconceptions and rumours
(uzushi) about the trial, its objectives and the risks or
benefits of gel use to be captured, and locally-appropriate
responses implemented. A number of uzushi related to
gel were highlighted by community representatives fol-
lowing the start of the MDP301 trial in Mwanza, such as
the gel being made from 'white men's sperm' or that gel
'makes you HIV positive". Rumours relating to the pur-
pose of the trial included the belief that the trial was
being conducted to allow women to be "experimented on
by white people" or that "white people are bringing drugs to
kill us". Community representatives told us that these
uzushi were circulating primarily in the broader Mwanza
community rather than among women already enrolled
in the trial (or those working in food and recreational
facilities who would be eligible to enrol), but it is possible
that similar views may be held by at least some women in
the trial cohort, which is obviously of concern. Data from
IDIs conducted during the trial supports the view of com-
munity representatives however, and suggests that partic-
ipants had sufficient knowledge, comprehension and
agency to dismiss rumours as untrue or simply irrelevant
gossip:
'Penye wengi hapakosi neno' [where many gather
words never lack]
'As for those rumours, because they can talk and if you
don't listen to them, they will talk for two or three days
then they will stop.'
Several uzushi noted during the feasibility study per-
sisted into the main trial, but appear to be far less widely
held in the community and/or been modified to reflect
trial-specific procedures. For example, related to the col-
lection of blood specimens, the concern that 'blood might
fall into the wrong hands and be sold for witchcraft pur-
poses', was prominent among study participants and com-
munity members during the feasibility study but have
largely disappeared following initiatives undertaken with
community representatives and the CAC [34,35]:
'There was a day when I didn't come and a woman
started telling them "ee she has gone to give blood,
she goes to give blood which is then sold" ...I told her
"it is not like they have to take my blood every day I go
there, it is every 3 months". After explaining this she
asked for forgiveness and now it is finished'
Concerns during the trial have instead re-focussed on
the amount of blood collected, as noted by several
respondents during IDIs:
'...they are taking too much blood...every time two bot-
tles'
'...every month you go there you must give blood. Two
bottles, in fact such things, according to how I live and
my work, you find that there is a problem. You can get
sick, and on that day you will have no blood'
This change of emphasis has occurred within the con-
text of increasing mutual trust and understanding
between women enrolled in the trial, potential partici-
pants, community members and the research team,
established through the community engagement model
developed in Mwanza [33,34], but also highlights the lim-
itations of the continuous consent process, since some
women remain unclear as to why blood is being collected
in the main trial.
Comprehension and retention of key messages
In the majority of IDIs conducted at all stages during fol-
low-up (Table 1), MDP301 trial participants in Mwanza
were able to appropriately recall and articulate key infor-
mation related to the potential non-protective effect of
gel, for example:
"At present I do not know... until after the results are
examined by those experts, they will know and will
inform us. But I am hopeful that it [gel] can help."
Among respondents who were asked if they thought gel
might protect them against HIV, many respondents
appeared to frame their thinking and to have internalised
key messages in terms broadly consistent with primary
trial outcomes. For example, many women said they were
'unsure' if the gel might be working, reasoning that the
trial is still on-going:
"I can't trust it [the gel] so much since it's still on trial"
"I am not sure about the gel because we haven't
reached the end of the study, we don't know yet if it
protects or not."
Women also conceptualised the potential benefits of
gel use within the context of their individual sexual lives,
prevailing socio-cultural contexts and norms. For exam-
ple, women who engage in commercial and transactional
sex in this setting are known to be at increased risk of
sexual coercion, gender-based and sexual violence [31]:
"I think the gel can protect against infections,
maybe...it can even protect against other infections
because you don't get bruises."
"That lubricant [gel] can protect against HIV/AIDS
infection because you don't get bruises... they say that
this gel doesn't have medicine...but that lubricant can
prevent you from getting bruises."
The effectiveness of consistent condom use for HIV
prevention and the need to continue using condoms even
in the context of participation in a vaginal microbicide
trial appeared to be broadly understood by the majority
(>90%, Table 1) of participants:
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"I am not sure [gel works] because it's on trial...that's
why I use condoms."
'I think it [condoms] protects but again I am not sure
because most of the people are using them but AIDS
still continues'
These findings need to be considered in the light of
data obtained during the feasibility and pilot studies in
Mwanza [31] and from similar at-risk cohorts in Tanzania
[26,28,37,38], which suggest that due to disparate prevail-
ing gender power relations and limited female sexual
agency in the context of transactional and commercial
sex, high levels of comprehension may translate only par-
tially into sexual behaviours that mitigate risk in this con-
text, as reflected in the relatively low use of condoms
during the feasibility study and phase III trial [25]. In
addition, several women highlighted locally-prevalent
rumours that condoms might be ineffective due to being
impregnated with viruses or that they contain holes hav-
ing been pierced, particularly those available in local
stores and other outlets as opposed to those provided by
the project:
'It also protects because the majorities are using con-
doms although they say that they [the condoms] are
being pierced. Now how is it pierced if you take it from
the shop without holes? They say ooh, others are
afraid, I have already checked a condom to see if it has
the viruses, if you take it and dry it in the sun you will
see the viruses. Now where do those viruses come from
while he has taken it from the packet and the packet
was intact? But someone will tell you - just try it and
see, you buy it from the shop and before you use it, just
tear the paper, pull out the condom and put it in clean
water or put on a metal sheet, you will see the viruses'
'There are other condoms that have holes'
In over 90% of IDIs conducted at all stages during fol-
low-up trial participants understood that they should
stop using gel if they suspected they might be pregnant.
How effective was the continuous consent process in 
Mwanza?
A participatory, multi-method, continuous informed
consent process achieved high levels of comprehension
and message retention among MDP301 trial participants
in Mwanza. This approach was based on experience
gained during earlier feasibility and pilot studies and in
particular, was informed through a dynamic engagement
with community representatives and stakeholders. Our
strategy shares a number of common elements with
approaches adopted among other vulnerable study popu-
lations, namely: a commitment to a continuous consent
process comprising the delivery of key information using
a variety of different media, at different time points, in a
variety of community and clinic-based settings, delivered
by staff trained in consent procedures from a variety of
different professional and disciplinary backgrounds
[18,23]. For example, in the HVTN903 HIV clinical trial
in Haiti [18], a short (8-minute) educational video was
shown to groups of 5-10 volunteers by a social worker,
who then introduced the trial consent form, discussed
key elements of the trial and responded to questions. The
following day, volunteers met a counsellor for a 30-min-
ute face-to-face discussion about the trial, after which a
psychologist conducted further discussion, completed a
comprehension form and provided immediate feedback
to subjects. Finally, formal written consent was obtained
in a subsequent meeting with a trial investigator. In con-
trast to the Mwanza model, further assessment and rein-
forcement of key messages during trial follow-up were
not part of the approach used in Haiti, nor were partici-
patory community liaison techniques employed to sup-
plement and inform the trial consent process.
These findings are encouraging but several important
caveats are worth noting. First, it remains unclear to what
extent informed choice to participate in the MDP301 trial
in Mwanza was based on a sound understanding of the
relative benefits and risks of trial participation or other
factors such as altruism, trust, individual priorities (e.g.
access to free, high-quality, readily accessible commu-
nity-based sexual and reproductive health care) or a com-
bination of these potential determinants. As Molyneux et
al have pointed out [14], key to this discourse is the con-
ceptual framework within which a decision to participate
is framed. For example, are terms used by the research
team to describe 'research', 'trial', 'experiment' or 'investi-
gation' (utafiti, jaribio, uvumbuzi and uchunguzi respec-
tively in Swahili) understood by women within the
research conceptual framework used by the research
team, or are all such terms considered by the majority of
participants within an individual therapeutic conceptual
framework and thereby to be synonymous with 'health
project' (mradi wa afya)? That is when we as researchers
talk of trial investigations and procedures during the
informed consent process, do volunteers conceptualise
these as being individually tailored activities, designed to
identity and address their own specific and individual
health needs? Given that health service delivery has
always been an integral component of the research pro-
gram in Mwanza [25] and highly regarded by partici-
pants, community members and local stakeholders alike
[34,35], it is likely that many trial participants may have
struggled with these competing constructs as they pro-
ceeded through the continuous consent process. Second,
the trust and partnership working practices established
between researchers and women in the Mwanza occupa-
tional cohort through the CLS may actually have exacer-
bated the complexities of informed decision making in
this context by increasing the risk of what has become
known as 'therapeutic misconception' (i.e. the belief that
Vallely et al. BMC Medical Ethics 2010, 11:10
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every aspect of the research has been designed to directly
benefit the individual) [14,39,40]. This then pervades an
individual participant's ability to truly understand and
internalise important trial concepts, particularly the dif-
ferences between placebo and active gel, and the potential
risks of trial participation. Third, a focus on a small num-
ber of key themes or messages and in reinforcing these at
regular intervals during an HIV prevention trial could
potentiate the risk that participants learn appropriate
responses by rote rather than facilitate a deeper under-
standing of trial objectives through questioning and open
reasoning during clinic visits or community-based con-
tact with research staff i.e. messages were not appropri-
ately internalised. A combination of message
reinforcement and open-ended discussion were used
throughout the continuous consent process in Mwanza to
minimise this risk. Qualitative data from the 256 IDIs
completed suggest, as summarised above, that MDP301
trial participants in Mwanza were able to gain a fairly
broad understanding of the research process and in par-
ticular, were able to conceptualise messages related to
trial participation within prevailing local socio-cultural
frameworks. A more detailed discussion of these issues
and related issues such as women's motivations for trial
participation are beyond the scope of this paper but will
be explored in depth in a subsequent publication (S Lees,
in draft).
Conclusions
A participatory, multi-method, continuous informed
consent process developed as part of the MDP301 trial in
Mwanza resulted in high levels of comprehension and
message retention among MDP301 trial participants in
Mwanza. This approach may represent a model for
researchers conducting HIV prevention trials among
other vulnerable at-risk populations in resource-poor set-
tings.
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